Cas­sava's prob­lems just got much worse as SEC launch­es probe in­to da­ta ma­nip­u­la­tion claims — re­port

The US Se­cu­ri­ties and Ex­change Com­mis­sion has launched a probe in­to claims that Cas­sa­va Sci­ences, an Austin-based drug de­vel­op­er, ma­nip­u­lat­ed da­ta key to its case for its ex­per­i­men­tal Alzheimer’s drug simu­fil­am, the Wall Street Jour­nal re­port­ed Wednes­day.

The re­port comes just two days af­ter Cas­sa­va in an SEC fil­ing re­vealed that “cer­tain gov­ern­ment agen­cies” had asked the biotech for doc­u­men­ta­tion. It wasn’t clear which agen­cies were in­quir­ing or what in­for­ma­tion they sought, and Cas­sa­va went out of its way to say the re­quests weren’t ac­cu­sa­tions of wrong­do­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER